Sharps Technology, Inc. (STSS)
NASDAQ: STSS · IEX Real-Time Price · USD
0.238
+0.004 (1.58%)
At close: Jul 2, 2024, 4:00 PM
0.231
-0.007 (-3.15%)
After-hours: Jul 2, 2024, 7:55 PM EDT
Company Description
Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems.
Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Sharps Technology, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 14, 2022 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Robert M. Hayes |
Contact Details
Address: 105 Maxess Road, Ste. 124 Melville, New York 11747 United States | |
| Phone | (631) 574 -4436 |
| Website | sharpstechnology.com |
Stock Details
| Ticker Symbol | STSS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.25 |
| CIK Code | 0001737995 |
| CUSIP Number | 82003F101 |
| ISIN Number | US82003F1012 |
| Employer ID | 82-3751728 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Hayes | Chief Executive Officer and Director |
| Andrew R. Crescenzo CPA | Chief Financial Officer |
| Ben Scheu | Senior Director of Sales |
| Dr. Steven Hertz M.D. | Chief Medical Officer |
| Adam S. Holdsworth | Managing Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 25, 2024 | PRER14A | Filing |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Jun 5, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 253G3 | Filing |
| Jun 4, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K/A | [Amend] Current report |
| May 31, 2024 | 8-K | Current Report |